Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention

Konstantinos Spargias, Elias Alexopoulos, Stamatis Kyrzopoulos, Panayiotis Iacovis, Darren C. Greenwood, Athanassios Manginas, Vassilis Voudris, Gregory Pavlides, Christopher E. Buller, Dimitrios Kremastinos, Dennis V. Cokkinos

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

Background - Contrast agents can cause a reduction in renal function that may be due to the generation of reactive oxygen species. Conflicting evidence suggests that administration of the antioxidant acetylcysteine prevents this renal impairment. The action of other antioxidant agents has not been investigated. Methods and Results - We conducted a randomized, double-blind, placebo-controlled trial of ascorbic acid in 231 patients with a serum creatinine concentration ≥1.2 mg/dL who underwent coronary angiography and/or intervention. Ascorbic acid, 3 g at least 2 hours before the procedure and 2 g in the night and the morning after the procedure, or placebo was administered orally. Contrast-mediated nephropathy was defined by an absolute increase of serum creatinine ≥0.5 mg/dL or a relative increase of ≥25% measured 2 to 5 days after the procedure. Contrast-mediated nephropathy occurred in 11 of the 118 patients (9%) in the ascorbic acid group and in 23 of the 113 patients (20%) in the placebo group (odds ratio [OR], 0.38; 95% confidence interval [CI], 0.17 to 0.85; P=0.02). The mean serum creatinine concentration increased significantly in the placebo group (from 1.36±0.50 to 1.50±0.54 mg/dL, P<0.001) and nonsignificantly in the ascorbic acid group (from 1.46±0.52 to 1.52±0.64 mg/dL, P=0.07). The mean increase in serum creatinine concentration was greater in the placebo group than in the ascorbic acid group (difference of 0.09 mg/dL; 95% CI, 0.00 to 0.17; P=0.049). Conclusions - Prophylactic oral administration of ascorbic acid may protect against contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure.

Original languageEnglish (US)
Pages (from-to)2837-2842
Number of pages6
JournalCirculation
Volume110
Issue number18
DOIs
StatePublished - Nov 2 2004

Fingerprint

Coronary Angiography
Ascorbic Acid
Kidney
Placebos
Creatinine
Serum
Antioxidants
Confidence Intervals
Acetylcysteine
Contrast Media
Oral Administration
Reactive Oxygen Species
Odds Ratio

Keywords

  • Angiography
  • Angioplasty
  • Antioxidants
  • Contrast media
  • Kidney

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Spargias, K., Alexopoulos, E., Kyrzopoulos, S., Iacovis, P., Greenwood, D. C., Manginas, A., ... Cokkinos, D. V. (2004). Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation, 110(18), 2837-2842. https://doi.org/10.1161/01.CIR.0000146396.19081.73

Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. / Spargias, Konstantinos; Alexopoulos, Elias; Kyrzopoulos, Stamatis; Iacovis, Panayiotis; Greenwood, Darren C.; Manginas, Athanassios; Voudris, Vassilis; Pavlides, Gregory; Buller, Christopher E.; Kremastinos, Dimitrios; Cokkinos, Dennis V.

In: Circulation, Vol. 110, No. 18, 02.11.2004, p. 2837-2842.

Research output: Contribution to journalArticle

Spargias, K, Alexopoulos, E, Kyrzopoulos, S, Iacovis, P, Greenwood, DC, Manginas, A, Voudris, V, Pavlides, G, Buller, CE, Kremastinos, D & Cokkinos, DV 2004, 'Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention', Circulation, vol. 110, no. 18, pp. 2837-2842. https://doi.org/10.1161/01.CIR.0000146396.19081.73
Spargias, Konstantinos ; Alexopoulos, Elias ; Kyrzopoulos, Stamatis ; Iacovis, Panayiotis ; Greenwood, Darren C. ; Manginas, Athanassios ; Voudris, Vassilis ; Pavlides, Gregory ; Buller, Christopher E. ; Kremastinos, Dimitrios ; Cokkinos, Dennis V. / Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. In: Circulation. 2004 ; Vol. 110, No. 18. pp. 2837-2842.
@article{edd18afb34bb4a20b027fa4d12e75814,
title = "Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention",
abstract = "Background - Contrast agents can cause a reduction in renal function that may be due to the generation of reactive oxygen species. Conflicting evidence suggests that administration of the antioxidant acetylcysteine prevents this renal impairment. The action of other antioxidant agents has not been investigated. Methods and Results - We conducted a randomized, double-blind, placebo-controlled trial of ascorbic acid in 231 patients with a serum creatinine concentration ≥1.2 mg/dL who underwent coronary angiography and/or intervention. Ascorbic acid, 3 g at least 2 hours before the procedure and 2 g in the night and the morning after the procedure, or placebo was administered orally. Contrast-mediated nephropathy was defined by an absolute increase of serum creatinine ≥0.5 mg/dL or a relative increase of ≥25{\%} measured 2 to 5 days after the procedure. Contrast-mediated nephropathy occurred in 11 of the 118 patients (9{\%}) in the ascorbic acid group and in 23 of the 113 patients (20{\%}) in the placebo group (odds ratio [OR], 0.38; 95{\%} confidence interval [CI], 0.17 to 0.85; P=0.02). The mean serum creatinine concentration increased significantly in the placebo group (from 1.36±0.50 to 1.50±0.54 mg/dL, P<0.001) and nonsignificantly in the ascorbic acid group (from 1.46±0.52 to 1.52±0.64 mg/dL, P=0.07). The mean increase in serum creatinine concentration was greater in the placebo group than in the ascorbic acid group (difference of 0.09 mg/dL; 95{\%} CI, 0.00 to 0.17; P=0.049). Conclusions - Prophylactic oral administration of ascorbic acid may protect against contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure.",
keywords = "Angiography, Angioplasty, Antioxidants, Contrast media, Kidney",
author = "Konstantinos Spargias and Elias Alexopoulos and Stamatis Kyrzopoulos and Panayiotis Iacovis and Greenwood, {Darren C.} and Athanassios Manginas and Vassilis Voudris and Gregory Pavlides and Buller, {Christopher E.} and Dimitrios Kremastinos and Cokkinos, {Dennis V.}",
year = "2004",
month = "11",
day = "2",
doi = "10.1161/01.CIR.0000146396.19081.73",
language = "English (US)",
volume = "110",
pages = "2837--2842",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention

AU - Spargias, Konstantinos

AU - Alexopoulos, Elias

AU - Kyrzopoulos, Stamatis

AU - Iacovis, Panayiotis

AU - Greenwood, Darren C.

AU - Manginas, Athanassios

AU - Voudris, Vassilis

AU - Pavlides, Gregory

AU - Buller, Christopher E.

AU - Kremastinos, Dimitrios

AU - Cokkinos, Dennis V.

PY - 2004/11/2

Y1 - 2004/11/2

N2 - Background - Contrast agents can cause a reduction in renal function that may be due to the generation of reactive oxygen species. Conflicting evidence suggests that administration of the antioxidant acetylcysteine prevents this renal impairment. The action of other antioxidant agents has not been investigated. Methods and Results - We conducted a randomized, double-blind, placebo-controlled trial of ascorbic acid in 231 patients with a serum creatinine concentration ≥1.2 mg/dL who underwent coronary angiography and/or intervention. Ascorbic acid, 3 g at least 2 hours before the procedure and 2 g in the night and the morning after the procedure, or placebo was administered orally. Contrast-mediated nephropathy was defined by an absolute increase of serum creatinine ≥0.5 mg/dL or a relative increase of ≥25% measured 2 to 5 days after the procedure. Contrast-mediated nephropathy occurred in 11 of the 118 patients (9%) in the ascorbic acid group and in 23 of the 113 patients (20%) in the placebo group (odds ratio [OR], 0.38; 95% confidence interval [CI], 0.17 to 0.85; P=0.02). The mean serum creatinine concentration increased significantly in the placebo group (from 1.36±0.50 to 1.50±0.54 mg/dL, P<0.001) and nonsignificantly in the ascorbic acid group (from 1.46±0.52 to 1.52±0.64 mg/dL, P=0.07). The mean increase in serum creatinine concentration was greater in the placebo group than in the ascorbic acid group (difference of 0.09 mg/dL; 95% CI, 0.00 to 0.17; P=0.049). Conclusions - Prophylactic oral administration of ascorbic acid may protect against contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure.

AB - Background - Contrast agents can cause a reduction in renal function that may be due to the generation of reactive oxygen species. Conflicting evidence suggests that administration of the antioxidant acetylcysteine prevents this renal impairment. The action of other antioxidant agents has not been investigated. Methods and Results - We conducted a randomized, double-blind, placebo-controlled trial of ascorbic acid in 231 patients with a serum creatinine concentration ≥1.2 mg/dL who underwent coronary angiography and/or intervention. Ascorbic acid, 3 g at least 2 hours before the procedure and 2 g in the night and the morning after the procedure, or placebo was administered orally. Contrast-mediated nephropathy was defined by an absolute increase of serum creatinine ≥0.5 mg/dL or a relative increase of ≥25% measured 2 to 5 days after the procedure. Contrast-mediated nephropathy occurred in 11 of the 118 patients (9%) in the ascorbic acid group and in 23 of the 113 patients (20%) in the placebo group (odds ratio [OR], 0.38; 95% confidence interval [CI], 0.17 to 0.85; P=0.02). The mean serum creatinine concentration increased significantly in the placebo group (from 1.36±0.50 to 1.50±0.54 mg/dL, P<0.001) and nonsignificantly in the ascorbic acid group (from 1.46±0.52 to 1.52±0.64 mg/dL, P=0.07). The mean increase in serum creatinine concentration was greater in the placebo group than in the ascorbic acid group (difference of 0.09 mg/dL; 95% CI, 0.00 to 0.17; P=0.049). Conclusions - Prophylactic oral administration of ascorbic acid may protect against contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure.

KW - Angiography

KW - Angioplasty

KW - Antioxidants

KW - Contrast media

KW - Kidney

UR - http://www.scopus.com/inward/record.url?scp=8144224968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8144224968&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000146396.19081.73

DO - 10.1161/01.CIR.0000146396.19081.73

M3 - Article

C2 - 15492300

AN - SCOPUS:8144224968

VL - 110

SP - 2837

EP - 2842

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 18

ER -